IKT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Inhibikase Therapeutics Inc (IKT) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While the stock has bullish technical indicators and favorable analyst ratings, the lack of recent positive news, weak financial performance, and absence of strong trading signals suggest holding off for now.
The MACD is positive and expanding, indicating bullish momentum. The RSI is in the neutral zone, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot point of 1.903, with resistance levels at 2.151 and 2.304, and support levels at 1.654 and 1.501.
Analysts have issued favorable ratings with price targets ranging from $4 to $8, citing strong mechanistic rationale and reduced development timelines for IKT-
Regulatory support for advancing IKT-001 directly into a pivotal Phase 3 trial.
Weak financial performance in Q3 2025, with no revenue growth and a significant net income loss of -$11.93M.
Lack of recent news or significant trading trends among hedge funds, insiders, or congress members.
No recent Intellectia Proprietary Trading Signals.
In Q3 2025, revenue remained at $0 with no growth. Net income improved YoY by 106.48% but still reported a loss of -$11.93M. EPS dropped significantly by -80.00% YoY, and gross margin remained at 0%.
Analysts from BofA, H.C. Wainwright, and Cantor Fitzgerald have issued Buy or Overweight ratings with price targets between $4 and $8, citing strong mechanistic rationale and reduced development timelines for IKT-001. However, they acknowledge the higher risk due to limited drug-specific data.
